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See related editorial on page 4. Cardiovascular disease is currently the leading cause of death amongAmerican women. Although the majority of these deaths can beattributed to coronary artery disease, a significant number ofwomen have valvular heart disease. In fact, of 123,000 patientsdischarged from the hospital in 1987 with diagnoses of aortic ormitral valve disease, 71% were women.1 In addition, more than
60% of heart valve replacement procedures are performed in women. In contrast,
39% of patients discharged from the hospital with diagnoses of myocardial infarc-
tion (MI) were women.2 Thus, while men are 15 times more likely to be discharged
with diagnoses of MI, women are just 4 times more likely to be discharged with
diagnoses of MI than vascular disease.1
Gender Differences in Pathophysiology of Valvular Heart Disease
Gender differences affect the pathophysiology of valvular heart disease. Women
have a 5% to 10% higher cardiac output (CO) at any level of submaximal oxygen
uptake than do men. The difference may be attributed to women’s lower hemoglobin
levels (10%). Women also have a maximal aerobic capacity that is 50% lower
than that of men (10%-15% lower when adjusted for lean body mass), which may
be related to lesser blood volume. In addition, women have greater capacity to
perform isotonic exercise, possibly because the estrogen influence on fatty acid is a
preferential energy substrate during exercise and sparing of glycogen stores.
Such gender differences have important implications in the care of women with
valvular heart disease. For example, because women are on average smaller than
men, it is best to index for body size when doing valve calculations. Also, women’s
higher CO means a higher valve gradient, which is important when calculating valve
area.
Pregnancy
Normal pregnancy is associated with a 30% to 50% increase in blood volume and
a related increase in CO. The volume changes begin in the first trimester and peak
by 20 to 24 weeks.3 Concurrently, heart rate increases by 10 to 20 beats per minute
and the stroke volume increases. Also, there is a substantial reduction in systemic
vascular resistance and a decrease in blood pressure. Clinically significant maternal
heart disease is uncommon during pregnancy (prevalence, 1%),4 but it does
increase the risk of adverse maternal, fetal, and neonatal outcomes5; ideally, patients
are aware of their valvular condition and prenatal risk when they are deciding
whether to have children. Both the American Heart Association and the American
College of Cardiology have classified maternal and fetal risk during pregnancy on
the basis of the type of valvular abnormality and by New York Heart Association
(NYHA) functional class.6
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Current guidelines state that moderate to severe valvular
stenosis (either mitral or aortic) is poorly tolerated during
pregnancy. Likewise, mitral or aortic regurgitation (with
NYHA class III-IV symptoms) increases risk because of the
increased volume load and CO during pregnancy.
Mitral Stenosis
There are gender differences in the pathophysiology of
mitral stenosis (MS), with a 3:1 female preponderance for
the condition. Calcification of the valves tends to occur later
in women than in men, providing a longer time window in
which balloon valvuloplasty can be performed, and perhaps
explaining why 82% of all mitral balloon valvuloplasty
candidates are women.
Mitral Stenosis and Pregnancy
Management of MS during pregnancy can be challenging,
and congestive heart failure, along with atrial fibrillation,
often may first appear with pregnancy, which can lead to
systemic embolism. If symptoms persist during the first
trimester despite diuretics, pregnancy may not be tolerated.
Therapeutic options (termination or valvuloplasty) must be
considered. Beta-blockers slow the maternal heart rate and
control symptoms, but these agents cross the placenta and
may also slow the fetal heart rate. Maternal mortality in
patients with severe MS is 5%. Labor, delivery, and the
immediate postpartum period are the times of greatest risk
of death. Surgery for MS can be performed during preg-
nancy, but there is a fetal death rate of 10%.
High-risk patients, such as those with severe symptoms
(NYHA class III or IV) or tight mitral stenosis (valve area
1.0 cm2), who undergo balloon mitral valvuloplasty or
valve surgery7 before conceiving appear to have fewer
complications during pregnancy than do women who are
treated medically. Women with severe symptoms during
pregnancy have undergone successful percutaneous balloon
mitral valvuloplasty during the second trimester, with nor-
mal subsequent deliveries and excellent fetal outcomes.8
Because radiation is of particular concern during pregnancy,
women who must be exposed to radiation during valvulo-
plasty procedures should have their uterus shielded and be
informed about the possible risks. Alternatively, mitral val-
vuloplasty can be performed with transesophageal echocar-
diographic guidance, reducing radiation risk. Pregnant
women with severe MS have also undergone open cardiac
surgery; maternal outcomes are similar to those of nonpreg-
nant patients, but the fetus may be lost in 10% to 30% of
cases.9
Aortic Valve Disease
Aortic valve disease, such as bicuspid aortic valve, non-
rheumatic valvular aortic stenosis, and diseases of the aorta
have a nearly 3:1 male predominance in clinical and autopsy
studies.10-12
Mitral Valve Prolapse
Early studies suggest a symptom complex for mitral valve
prolapse (MVP) that includes chest pain, dyspnea, palpita-
tions, syncope, anxiety, panic attacks, bony thoracic abnor-
malities, asthenic habitus, and echocardiographic abnormal-
ities.13-15 However, more recent and rigorous studies have
cast doubt that these findings are more common in MVP
than in control subjects. Data from the Framingham study
suggest that people with MVP display a far more benign
profile of associated valvular, atrial, and ventricular abnor-
malities than previously reported in hospital- or referral-
based series.16 Another study from Cornell compared first-
degree relatives of MVP to first-degree relatives of their
unaffected spouse and found differences in midsystolic
clicks, thoracic abnormalities, and palpitations but not atyp-
ical chest pain, dyspnea, panic attacks, trait anxiety score,
and electrocardiogram-inferior abnormalities.17 Thus, it ap-
pears that the use of nonrigorous criteria, such as 4-chamber
echocardiography, led to the condition being overdiag-
nosed. Newer criteria by Levine and colleagues18 have
allowed for the more accurate and less frequent diagnosis of
MVP. These criteria, combined with the recognition of the
benign nature of MVP (especially in women) and the atten-
dant problems to labeling valvular variants as a disease,
have led to a decrease in the number of MVP diagnoses.
Use of Prosthetic Valves in Pregnancy
Mechanical prostheses present particular disadvantages for
women of childbearing age because they require a rigor-
ously maintained, noncoumadin anticoagulation regimen
such as unfractionated or low-molecular-weight heparin
during pregnancy (coumadin is a known teratogen). Despite
careful anticoagulation, there remains a high risk for throm-
boembolism and fetal hemorrhage. In addition, there is an
18% structural valve failure rate in pregnant women with
bioprosthetic valves. Prosthetic valve failure in the mitral
position occurs approximately 2.5 to 8 years earlier than
expected in the life span of the prosthesis.19
Summary
Because of differences in pathophysiology and body size, as
well as the special considerations during pregnancy, man-
agement and outcomes for valvular surgery differ in
women. Overall, rates of rheumatic heart disease continue
to fall, as do valve replacements related to rheumatic dis-
ease. Continued research is necessary to optimize our care
of women with valvular disease, particularly the challeng-
ing care of women with serious valvular heart disease
during pregnancy.
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